Harel is the Winner of Department for International Trade (DIT)’s first-ever European Women in Tech; Finalist of the Quesnay’s Female Founders in InsurTech and the Insurtech Hartford Challenge 2021; Serenus.AI Granted New US Patent for ‘AUTOMATED METHOD AND SYSTEM FOR SCREENING AND PREVENTION OF UNNECESSARY MEDICAL PROCEDURES’
Hillary (Orly) Harel (ADV), Co-Founder and CEO of Serenus.AI relates to the visit of Dr. Moshe Bareket, the Director General of the Capital. Markets, Insurance & Savings Authority at the final event of the Israeli Insurtech Accelerator event:
“When a senior government representative participates in such an event, it shows the willingness of the government to advance innovation in the field and to signal all the relevant stakeholders, private and government insurance companies, to invest in innovation and implement it in the organization”.
Serenus.AI is a graduate of the First Cohort of the Insurtech Israel Accelerator, initiative of Insurtech Israel and partners Ayalon Insurance Company and BrokerTech Ventures.
Harel is the Winner of Department for International Trade (DIT)’s first-ever European Women in Tech, finalist of the Quesnay’s Female Founders in InsurTech and the Insurtech Hartford Challenge 2021.
Harel relates to the accelerator and says that the company’s participation in the program allowed it to be exposed to new growth channels, as well as present its unique solution to potential customers and investors and meet and advise with leading mentors in the field.
“For example, one of the interesting lectures was given by Mr. Rob Galbraith, Insurance Futurist and Key Opinion Leader, providing an overview about the US insurance world and methods to effectively penetrate the US market.”
With a US registered patent and three patents pending, Serenus.AI Ltd. presents a novel AI-based solution that assists medical professionals, health systems and insurers in making better medical treatment decisions, saving lives and valuable resources.
This innovative cloud-based platform uses unique algorithms that replicate the objective decision-making process of top physicians. This is achieved by combining the best, up to date medical practice guidance, experienced professionals’ knowledge and machine learning technologies. This results in a unique value proposition that benefits patients, physicians and insurers by implementing a uniform objective medical standard across entire health systems.
For patients, Serenus.AI prevents unnecessary risks and costs, improving the level of care. For the physician, it provides a real-time decision support system for each case and decreases the probability of clinical errors. For insurers, it improves the workflow for physicians, improves efficiencies and saves valuable resources.
While the system-generated report helps physicians and utilization managers clearly understand how the Serenus.AI software arrived at its recommendations, the final decision is always made by the professional at his or her discretion. Serenus.AI does not collect any personal identifiable information to ensure that the privacy of the patient is paramount.
Serenus.AI’s go to market strategy begins with medical procedures and payers, including personal and employer-funded health plans in the US, as well as national health services in overseas markets. In the US, Serenus.AI is focusing on the prior-authorization market, partnering with private health plans and working with employers, using artificial intelligence and machine learning to optimize the utilization process, as well as providing an informative platform for patients to make informed medical decisions.
The company has already developed modules for 30 of the most common and costly procedures, which are shown to have the highest risk of being unnecessary. Doing so reduces Serenus.AI’s customers’ medical and administrative costs, boosting satisfaction across the board, and advancing the quality of care and effectiveness.